GlassScriptPhysician profile
Charles C Greene
NPI 1306876651
$19,040.00
in general payments reported to CMS, 2019-2025
27 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 92% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,697 · 2020: $1,850 · 2021: $534 · 2022: $2,950 · 2023: $1,886 · 2024: $2,709 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,538 · Consulting Fee: $974 · Debt Forgiveness: $359 · Long Term Medical Supply Or Device Loan: $105 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,538.31 |
| Consulting Fee | $974.00 |
| Debt Forgiveness | $359.02 |
| Long Term Medical Supply Or Device Loan | $104.85 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $4,559.33 | 2019-2025 | |
| Aerin Medical INC. | $4,063.09 | 2019-2025 | |
| Intersect Ent, INC. | $3,573.58 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,766.36 | 2022 | |
| Genzyme Corporation | $1,398.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $957.58 | 2019-2025 | Dupixent |
| Stryker Corporation | $461.60 | 2019-2024 | Fiagon Navigation Unit |
| Photonicare INC | $381.36 | 2024 | Otosight Middle Ear Scope |
| Novartis Pharmaceuticals Corporation | $343.30 | 2019-2021 | |
| Glaxosmithkline, LLC. | $308.81 | 2022-2025 | Nucala |
| Inspire Medical Systems, INC. | $165.41 | 2023 | Inspire |
| Medtronic, INC. | $137.04 | 2024-2025 | Propel, Nim Vital |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Novo Nordisk INC | $114.57 | 2019 | |
| Ethicon US, LLC | $112.82 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $104.85 | 2024 | Hillrom - Spot Vision Screener |
| Acclarent, INC | $96.44 | 2019-2020 | |
| Smith+Nephew, INC. | $77.78 | 2019 | |
| Amgen INC. | $56.45 | 2025 | Tezspire |
| Alk-Abello, INC | $42.04 | 2019-2021 | |
| Linvatec Corporation | $40.79 | 2024 | Conmed 3dhd Video Systems, Linvatec 2dhd Video Systems |
| Merck Sharp & Dohme LLC | $33.52 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $33.44 | 2023-2024 | Ryaltris |
| Galderma Laboratories, L.P. | $32.77 | 2022-2023 | |
| Depuy Synthes Sales INC. | $25.28 | 2024 | N/A |
| Kaleo, INC. | $14.98 | 2020 | |
| Olympus America INC. | $13.75 | 2023 | Rhino-Laryngo Videoscope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.